Sickle Cell Disease & Hemoglobin Variants

Molecular basis and pathophysiology

The mutation. Sickle hemoglobin arises from an A→T point mutation in codon 6 of the β-globin gene (HBB, chromosome 11) that replaces hydrophilic glutamate with hydrophobic valine; HbS is α₂β^S₂. Inheritance is autosomal recessive. Homozygous HbSS is sickle cell anemia; HbS combined with HbC (HbSC) or with a β-thalassemia allele (HbS-β⁰, clinically like HbSS, or the milder HbS-β⁺) produces other sickle syndromes.

Polymerization. When HbS gives up oxygen, the valine docks into a hydrophobic pocket on a β chain of a neighboring molecule, and deoxy-HbS assembles into long polymer fibers that distort the red cell into a rigid sickle. Reoxygenation can reverse early sickling, but repeated cycles damage the membrane and dehydrate the cell through potassium loss via Gardos channels, leaving irreversibly sickled cells. These rigid cells obstruct microvessels (vaso-occlusion) and are destroyed both in the spleen and within vessels (hemolysis).

Triggers. Polymerization speeds up whenever the deoxy-HbS fraction or its concentration rises:

• Hypoxia: high altitude, lung disease, acute chest syndrome.
• Acidosis and fever: right shift of the O₂ dissociation curve and more unloading.
• Dehydration: higher MCHC; the polymerization rate rises steeply with intracellular HbS concentration.
• Infection, cold exposure and sluggish flow.

For the same reason, coinherited α-thalassemia, which lowers MCHC, reduces hemolysis.

Fetal hemoglobin protection. The γ chains of HbF (α₂γ₂) cannot join HbS polymers. At birth HbF makes up about 60–80% of hemoglobin, so newborns are well; symptoms appear around 6 months as the γ→β switch completes, often as dactylitis. People who keep high HbF levels, such as those coinheriting hereditary persistence of fetal hemoglobin (who have little or no disease despite lacking HbA), or those treated with hydroxyurea, have milder courses.

Hemolysis and its consequences

Laboratory picture. Sickled red cells survive about 10–20 days instead of 120. In HbSS the baseline hemoglobin is about 6–9 g/dL with a high reticulocyte count, raised indirect bilirubin and LDH, and low haptoglobin. The smear shows sickle cells, target cells and, once the spleen has infarcted, Howell-Jolly bodies.

Nitric oxide scavenging. Free hemoglobin released by intravascular hemolysis consumes nitric oxide, promoting vasoconstriction and endothelial dysfunction. This hemolysis-driven vasculopathy contributes to pulmonary hypertension, leg ulcers and priapism.

Pigment gallstones. Chronic bilirubin overload precipitates black calcium bilirubinate stones, which can cause cholecystitis even in children.

Vaso-occlusive and organ complications

Acute chest syndrome. This is a leading cause of death in sickle cell disease. It often follows a pain crisis involving the ribs, where splinting and marrow fat embolism combine with infection by atypical bacteria or viruses.

Stroke prevention. Transcranial Doppler measures flow velocity in the large intracranial arteries; a time-averaged mean velocity of 200 cm/s or more prompts chronic transfusion to keep HbS below 30%, which lowers the risk of a first stroke by about 90%. Silent cerebral infarcts on MRI are even more common than overt strokes and impair learning.

Kidney. Loss of the medullary countercurrent gradient produces isosthenuria (nocturia, enuresis, easy dehydration), and papillary necrosis produces gross hematuria and flank pain with sloughed papillae. Both also occur in sickle trait. Glomerular hyperfiltration later leads to proteinuria, FSGS and CKD.

Priapism and bone. Prolonged or recurrent priapism causes corporal fibrosis and erectile dysfunction. Osteomyelitis settles in infarcted bone and is classically caused by Salmonella (a motile, H₂S-producing, non-lactose-fermenting gram-negative rod), which enters through gut microinfarcts and escapes clearance because of functional asplenia; Staphylococcus aureus remains common.

Spleen, infection and anemic crises

Autosplenectomy. Repeated splenic infarction produces functional asplenia in infancy and a small fibrotic spleen by about age 5 in HbSS. Howell-Jolly bodies appear, and the risk of overwhelming sepsis from encapsulated organisms (S. pneumoniae, H. influenzae type b, N. meningitidis) and Salmonella rises sharply. Prevention is penicillin prophylaxis from 2 months to 5 years plus pneumococcal, meningococcal and Hib vaccines. Fever of 38.5 °C or more in a child with sickle cell disease is an emergency requiring blood culture and IV ceftriaxone without delay.

Splenic sequestration. In young children whose spleens still function (usually under 5 years in HbSS, older in HbSC), sickled cells suddenly pool in the spleen. The spleen enlarges rapidly, hemoglobin falls by 2 g/dL or more, platelets drop and hypovolemic shock can follow; reticulocytes stay high. Treatment is cautious transfusion, and recurrent episodes may need splenectomy; parents are taught to palpate the spleen.

Aplastic crisis. Parvovirus B19 enters erythroid progenitors through the P antigen (globoside) and halts red cell production for about 7–10 days. With 120-day red cells this passes unnoticed, but with 10–20-day sickle cells hemoglobin plummets while reticulocytes fall near zero. Treatment is transfusion; patients are contagious and are kept away from pregnant contacts.

Sickle trait, HbC and HbSC

Sickle trait (HbAS). About 1 in 13 Black or African American newborns carries the trait. Red cells contain about 40% HbS and rarely sickle in the circulation. The trait protects against severe P. falciparum malaria: parasitized cells sickle more readily and are cleared by the spleen, a balanced polymorphism that explains the high HbS frequency where malaria is endemic. Clinical clues include painless hematuria from papillary necrosis, isosthenuria, renal medullary carcinoma (an aggressive SMARCB1-deficient tumor of young people) and exertional rhabdomyolysis or collapse with extreme exertion, heat and dehydration.

HbC. Lysine replaces glutamate at position 6. HbC does not polymerize; it crystallizes into rod-shaped intracellular crystals and dehydrates red cells, producing target cells, a high MCHC, mild hemolysis and splenomegaly in HbCC. HbSC disease is milder than HbSS, with higher hemoglobin, fewer crises and a spleen that often persists into adulthood, but proliferative retinopathy and avascular necrosis are prominent.

Diagnosis and treatment

Electrophoresis. At alkaline pH hemoglobin is negatively charged and migrates toward the anode. Losing glutamate's negative charge slows HbS, and gaining lysine's positive charge slows HbC further, so the order from the anode is A > F > S > C. Universal newborn screening by HPLC or isoelectric focusing reports FS for HbSS or HbS-β⁰ (no normal β allele), FAS for trait and FSC for HbSC. A sickling solubility test detects HbS but cannot distinguish trait from disease and is unreliable in newborns with high HbF.

Hydroxyurea. It inhibits ribonucleotide reductase; the resulting stress erythropoiesis reactivates γ-globin and raises HbF, and it also lowers neutrophil counts and red cell adhesion. It reduces pain crises, acute chest syndrome, transfusion needs and mortality and is offered from 9 months of age in HbSS. Adverse effects are myelosuppression (monitor the CBC) and teratogenicity; a rising MCV is a handy marker of adherence.

Other therapies.

• L-glutamine raises red cell NAD redox capacity, lowering oxidative stress and crisis frequency.
• Transfusion, simple or exchange, treats acute stroke, severe acute chest syndrome and sequestration and prevents stroke after an abnormal TCD; chronic transfusion causes iron overload treated with deferasirox or deferoxamine.
• Hematopoietic stem cell transplant from a matched sibling is curative.
• Gene therapy is approved for severe disease: exa-cel uses CRISPR to disrupt the BCL11A erythroid enhancer and raise HbF, and lovo-cel adds an anti-sickling β-globin gene with a lentiviral vector.

Match drug to mechanism: hydroxyurea raises HbF, L-glutamine raises NAD redox capacity, and crizanlizumab blocks P-selectin-mediated cell adhesion.